RLMD (Relmada Therapeutics) OCF Margin %: 0.00% (As of Mar. 2026)


RLMD Relmada Therapeutics Inc RLMD
29 GF Score
Price $6.67
! 2 Warning Signs
View Full Analysis

What is Relmada Therapeutics OCF Margin %?

Relmada Therapeutics RLMD +3.72% 29 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates RLMD with a GF Score™ of 29/100. The stock has 2 warning signs investors should review. Among 959 Biotechnology companies, Relmada Therapeutics ranks worse than 104275.18% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Relmada Therapeutics's Cash Flow from Operations for the three months ended in Mar. 2026 was $-15.07 Mil. Relmada Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Relmada Therapeutics's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Relmada Therapeutics's current OCF Yield % is -6.09%.

The historical rank and industry rank for Relmada Therapeutics's OCF Margin % or its related term are showing as below:


RLMD's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -66.52
* Ranked among companies with meaningful OCF Margin % only.

Relmada Therapeutics OCF Margin % Related Terms

Relmada Therapeutics OCF Margin % Historical Data

* Premium members only.

The historical data trend for Relmada Therapeutics's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Relmada Therapeutics OCF Margin % Chart

Relmada Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Relmada Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
RLMD
29GF Score
Relmada Therapeutics Inc RLMD
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Relmada Therapeutics OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Relmada Therapeutics's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-45.787/0
= %

Relmada Therapeutics's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-15.067/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Relmada Therapeutics (RLMD) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Relmada Therapeutics and its competitors. According to the industry distribution chart, Relmada Therapeutics ranks #999999 out of 959 companies in the Biotechnology industry.
Is Relmada Therapeutics' OCF Margin % too high?
Relmada Therapeutics' current OCF Margin % is 0.00%. Based on the distribution chart, Relmada Therapeutics ranks #999999 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Relmada Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Relmada Therapeutics' OCF Margin % compare to ALLO and PHAT?
According to the Biotechnology industry distribution chart, Relmada Therapeutics ranks #999999 out of 959 companies for OCF Margin %. This places Relmada Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Relmada Therapeutics and its competitors. Relmada Therapeutics's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Relmada Therapeutics stock overvalued right now?
Relmada Therapeutics (RLMD) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Relmada Therapeutics' overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Relmada Therapeutics (RLMD), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Relmada Therapeutics Business Description

Other Exchanges 4E2:Germany
Address 2222 Ponce de Leon Boulevard, Floor 3, Coral Gables, FL, USA, 33134
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.
29GF Score

Get the complete analysis for RLMD

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.67
Price